Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 6, 2006

Affymetrix and NimbleGen Systems Enter into Licensing Agreement

  • NimbleGen Systems obtained a nonexclusive, worldwide license to a number of Affymetrix patents covering the manufacture, use, and sales of nucleic acid microarrays and related products and services in the research field.

    “This licensing agreement with NimbleGen follows from a commercial relationship and enables both companies to better serve customers within the growing microarray market,” says Alan Sherr, vp and chief counsel for licensing at Affymetrix.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »